Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) is a rare, inherited eye disease caused by mutations in the CAPN5 gene, which encodes the enzyme calpain-5 in retinal photoreceptor cells. Over decades, it leads to chronic inflammation, abnormal blood vessel growth, fibrotic scarring, and progressive vision loss, ultimately resulting in complete blindness if untreated PLOSPLOS.

Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) is a rare, inherited eye disease caused by mutations in the CAPN5 gene, which encodes the calcium-activated protease calpain-5. Over decades, patients develop progressive inflammation of the uveal tract (uveitis), degeneration of photoreceptors (like retinitis pigmentosa), and abnormal new blood vessel growth (neovascularization) in the retina and iris, often complicated by vitreous hemorrhage and tractional retinal detachment EyeWikiPLOS.
Most affected families harbor missense mutations (e.g., Arg243Leu, Leu244Pro) in the catalytic domain of CAPN5, leading to mislocalization of the enzyme and dysregulated proteolysis that triggers inflammation and angiogenesis EyeWikiPMC. Clinically, ADNIV typically begins in the second or third decade of life and follows five stages—initial uveitis, photoreceptor loss, retinal neovascularization, intraocular fibrosis with detachment, and finally phthisis bulbi (eye shrinkage) PLOSPMC.

ADNIV is unique in that it mimics common eye conditions at different stages: it begins like an autoimmune uveitis, evolves into a degeneration resembling retinitis pigmentosa, then progresses to a proliferative diabetic retinopathy–type neovascularization, and finally to fibrotic tractional retinal detachment, neovascular glaucoma, and phthisis bulbi PLOSPLOS.

Types (Stages)

ADNIV advances through five chronologic stages, each roughly a decade long. Below are descriptions of each stage:

Stage I

In stage I, patients exhibit mild, non-infectious uveitis with occasional white blood cells in the vitreous and a subtle reduction in the ERG b-wave, although the retina appears normal on exam PLOS.

Stage II

Stage II resembles retinitis pigmentosa as photoreceptor cells begin degenerating, leading to peripheral pigmentary changes and early cataract formation PLOS.

Stage III

In stage III, abnormal new blood vessels form on the retina and iris—similar to proliferative diabetic retinopathy—often resulting in cystoid macular edema and floaters from early hemorrhage PLOS.

Stage IV

Stage IV is marked by intraocular fibrosis. Fibrotic membranes contract, causing tractional retinal detachments and more extensive vitreous hemorrhages, which significantly impair vision PLOS.

Stage V

The final stage involves relentless inflammation, widespread hemorrhage, neovascular glaucoma, ongoing fibrosis, and ultimately phthisis bulbi, where the eye shrinks and loses all function PLOS.

Causes

1. CAPN5 gene mutation
   A missense mutation in the CAPN5 gene is the fundamental cause of ADNIV, transmitted in an autosomal dominant pattern with complete penetrance PLOS.

2. Exon 6 catalytic-domain alterations
   Mutations occur in exon 6 of CAPN5, affecting two adjacent amino acids critical for the enzyme’s catalytic activity PLOS.

3. Mislocalization of calpain-5
   Disease-causing variants shift calpain-5 from its normal cell-membrane location to the cytosol, unsettling its regulation PLOS.

4. Calcium-sensitive domain disruption
   The mutations lie within a calcium-binding domain, altering the enzyme’s activation threshold and response to calcium signals PLOS.

5. Aberrant protease activity
   Structural changes near the enzyme’s active site result in unregulated proteolysis of intracellular proteins PLOS.

6. Gain-of-function mechanism
   Unlike loss-of-function disorders, these mutations enhance calpain-5 activity, perpetuating tissue damage PLOS.

7. Photoreceptor synapse dysfunction
   Calpain-5 normally modulates synaptic proteins; its mutated form disrupts photoreceptor-to-bipolar cell signaling, seen as ERG abnormalities PLOS.

8. Intracellular signaling imbalance
   Excessive protease activity perturbs signaling networks that regulate cell survival, inflammation, and repair in the retina PLOS.

9. Autoimmune activation
   Misprocessing of retinal proteins triggers autoimmune responses, leading to sterile inflammation inside the eye PLOS.

10. Immune cell infiltration
    Clusters of leukocytes invade the vitreous cavity, driving chronic uveitis and tissue injury PLOS.

11. Blood–retinal barrier breakdown
    Inflammation compromises vessel integrity, allowing fluid to leak into the macula and cause edema PLOS.

12. Pathologic neovascular growth
    Inflammatory signals promote abnormal new vessel formation on the retina and iris, which are fragile and prone to bleeding PLOS.

13. Fibrotic membrane formation
    Persistent inflammation stimulates fibrous tissue deposition on retinal surfaces, leading to traction PLOS.

14. Vitreous hemorrhage
    Fragile new vessels rupture easily, filling the vitreous cavity with blood and blocking vision PLOS.

15. Neovascular glaucoma
    Aberrant vessels grow into the anterior chamber angle, impeding fluid outflow and raising intraocular pressure PLOS.

Symptoms

1. Vision loss
   Gradual decrease in visual acuity occurs as photoreceptors degenerate and macular edema develops PLOS.

2. Eye pain and redness
   Mild to moderate discomfort and redness accompany the intraocular inflammation of early stages PLOS.

3. Photophobia
   Sensitivity to light arises from uveitis-related breakdown of the blood–aqueous barrier PLOS.

4. Floaters
   Patients often note moving spots in their vision due to inflammatory cells or hemorrhages in the vitreous PLOS.

5. Night blindness
   Early photoreceptor dysfunction leads to difficulty seeing in low-light conditions PLOS.

6. Metamorphopsia
   Distorted or wavy central vision results from macular edema and epiretinal membrane formation PLOS.

7. Cataract development
   Posterior subcapsular cataracts form prematurely, further reducing clarity of vision PLOS.

8. Peripheral vision loss
   Retinal detachment and pigmentary degeneration shrink the visual field PLOS.

9. Intraocular pressure spikes
   Neovascular and proliferative angle closure glaucoma cause episodic or sustained hypertension in the eye PLOS.

10. End-stage phthisis bulbi
    In advanced disease, the eye becomes shrunken, disorganized, and non-functional PLOS.

Diagnostic Tests

Physical Examination

1. Visual Acuity Test
   Measures the smallest letters a patient can read on a standardized chart, tracking progression of vision loss EyeWiki.

2. Tonometry
   Gauges intraocular pressure to detect early neovascular glaucoma and steroid-induced spikes EyeWiki.

Manual Ophthalmic Examinations

3. Slit-Lamp Examination
   Uses a biomicroscope to inspect the anterior segment for cells, flare, and cataracts EyeWiki.

4. Gonioscopy
   Assesses the angle between the iris and cornea for neovascularization and angle-closure risk EyeWiki.

Laboratory and Pathological Tests

5. Complete Blood Count (CBC)
   Screens for systemic inflammation and infection when uveitis is prominent EyeWiki.

6. Erythrocyte Sedimentation Rate (ESR)
   Indicates nonspecific inflammatory activity that may accompany ocular inflammation EyeWiki.

7. C-Reactive Protein (CRP)
   Another marker of systemic inflammation useful when ruling out infectious uveitis EyeWiki.

8. Tuberculin Skin Test / IGRA
   Evaluates latent tuberculosis in patients with unexplained intraocular inflammation EyeWiki.

9. RPR (Rapid Plasma Reagin)
   Screens for syphilis, a treatable cause of posterior uveitis EyeWiki.

10. Genetic Testing for CAPN5
    Confirms the diagnosis by identifying pathogenic CAPN5 missense mutations PLOS.

Electrodiagnostic Tests

11. Electroretinography (ERG)
    Detects early loss of the scotopic b-wave, indicating photoreceptor synapse dysfunction PLOS.

12. Visual Evoked Potentials (VEP)
    Measures cortical responses to visual stimuli to assess optic nerve integrity EyeWiki.

13. Electro-oculography (EOG)
    Assesses RPE function by measuring the standing potential between cornea and retina EyeWiki.

Imaging Tests

14. Fundus Photography
    Documents the appearance of the retina, neovascular changes, and pigmentary degeneration EyeWiki.

15. Fluorescein Angiography (FA)
    Visualizes blood-retinal barrier breakdown and areas of neovascular leakage PLOSEyeWiki.

16. Optical Coherence Tomography (OCT)
    Provides cross-sectional images of the retina to detect macular edema and epiretinal membranes EyeWiki.

17. B-Scan Ultrasonography
    Detects dense vitreous hemorrhage and tractional detachments when view is obscured EyeWiki.

18. Indocyanine Green Angiography (ICGA)
    Highlights choroidal vasculature to evaluate deeper neovascularization EyeWiki.

19. Fundus Autofluorescence
    Maps RPE integrity by detecting lipofuscin accumulation in degenerating photoreceptors EyeWiki.

20. Widefield Retinal Imaging
    Captures peripheral retinal changes and vitreoretinal traction in advanced stages EyeWiki.

Non-Pharmacological Treatments

Below are twenty supportive and self-management strategies—categorized into exercise therapies, mind-body practices, and educational/self-management interventions—each explained in simple language with purpose and mechanism.

Exercise Therapies

1. Brisk Walking
   Description: Gentle, sustained walking for 30 minutes most days.
   Purpose: Improves overall circulation and may reduce ocular inflammation.
   Mechanism: Regular aerobic exercise modulates immune cells and lowers pro-inflammatory cytokines that could exacerbate uveitis and neovascularization KargerPMC.

2. Resistance Training
   Description: Light weights or resistance bands targeting major muscle groups, 2–3× weekly.
   Purpose: Builds strength, supports daily function, and may counter muscle loss from chronic inflammation.
   Mechanism: Increases anti-inflammatory myokines (e.g., IL-6) that help resolve systemic inflammation KargerPMC.

3. Ocular Mobility Exercises
   Description: Slow, controlled eye movements (up, down, side-to-side) for 5–10 minutes daily.
   Purpose: Maintains flexibility of extraocular muscles and eases strain.
   Mechanism: Promotes micro-circulation in periocular tissues, which can aid fluid turnover in the vitreous cavity PatientUveitis.org | OIUF.

4. Vision Rehabilitation Drills
   Description: Tracking moving targets on a screen or card, 15 minutes daily.
   Purpose: Slows progression of photoreceptor loss by stimulating surviving retinal cells.
   Mechanism: Neuroplasticity—repeated visual stimulation enhances synaptic strength in visual pathways PatientPMC.

5. Balance and Coordination Tasks
   Description: Tai chi–style weight shifts or standing on a foam pad.
   Purpose: Improves proprioception to prevent falls and promote confidence in mobility.
   Mechanism: Engages vestibular and cerebellar circuits, indirectly supporting ocular motor control KargerPMC.

Mind-Body Practices

6. Mindfulness Meditation
   Description: 10–20 minutes of guided breathing and present-moment focus.
   Purpose: Reduces stress that can trigger inflammatory flares.
   Mechanism: Lowers cortisol and sympathetic activation, dampening immune over-reactivity KargerAAO.

7. Yoga
   Description: Gentle postures (asanas) with breath awareness, 2–3× weekly.
   Purpose: Enhances flexibility, reduces tension around head and neck, and calms the mind.
   Mechanism: Combines low-impact movement with parasympathetic activation to curb inflammation KargerAAO.

8. Tai Chi
   Description: Flowing, low-impact martial art movements, 1-hour sessions.
   Purpose: Improves balance, reduces stress, and supports immune regulation.
   Mechanism: Synchronizes breath with motion, boosting vagal tone and lowering inflammatory markers KargerPMC.

9. Guided Imagery
   Description: Visualization exercises imagining healing light in the eyes.
   Purpose: Eases anxiety and promotes a sense of control over illness.
   Mechanism: Influences limbic system to reduce stress hormone release KargerUveitis.org | OIUF.

10. Deep-Breathing Techniques
    Description: 4-7-8 breathing (inhale 4s, hold 7s, exhale 8s) for 5 minutes.
    Purpose: Quickly calms the nervous system during acute discomfort or anxiety.
    Mechanism: Shifts autonomic balance toward parasympathetic dominance, which inhibits inflammatory cascades KargerAAO.

Educational & Self-Management Interventions

11. Structured Patient Education Sessions
    Description: Regular classes or webinars about ADNIV and uveitis management.
    Purpose: Empowers patients with knowledge to adhere to treatments and recognize flares.
    Mechanism: Better understanding leads to earlier self-reporting of symptoms and timely intervention Uveitis.org | OIUFAAO.

12. Support Group Participation
    Description: Monthly meetings (in-person or online) with fellow ADNIV patients.
    Purpose: Provides emotional support and practical tips from peers.
    Mechanism: Social connectedness reduces stress and encourages healthy coping strategies Uveitis.org | OIUFUveitis.org | OIUF.

13. Symptom Self-Monitoring
    Description: Daily log of vision changes, pain, and floaters in a journal or app.
    Purpose: Helps detect subtle worsening before major complications arise.
    Mechanism: Early detection prompts faster clinical review and treatment adjustment Uveitis.org | OIUFPatient.

14. Treatment Adherence Aids
    Description: Pillboxes, alarms, or medication-tracking apps.
    Purpose: Ensures consistent dosing of eye drops and systemic drugs.
    Mechanism: Reduces variability in drug levels, preventing flare-ups from missed doses PMCWebMD.

15. Personalized Action Plans
    Description: Written plan outlining what to do at first sign of worsening.
    Purpose: Clears confusion during new symptoms, speeding self-care actions.
    Mechanism: Having predefined steps reduces decision fatigue and delays Uveitis.org | OIUFAAO.

16. Telemedicine Check-Ins
    Description: Scheduled video visits with ocular immunologists.
    Purpose: Maintains close follow-up without travel barriers.
    Mechanism: Regular remote reviews catch flares early and adjust therapies promptly Uveitis.org | OIUFAAO.

17. Online Educational Modules
    Description: Interactive e-learning about uveitis, genetics, and lifestyle.
    Purpose: Reinforces knowledge at one’s own pace and revisits complex topics.
    Mechanism: Multimedia content boosts retention and self-efficacy Uveitis.org | OIUFUveitis.org | OIUF.

18. Peer Mentoring Programs
    Description: Pairing newly diagnosed patients with veteran ADNIV mentors.
    Purpose: Offers firsthand coping strategies and practical advice.
    Mechanism: Role modeling by experienced patients fosters constructive behaviors Uveitis.org | OIUFUveitis.org | OIUF.

19. Stress Management Workshops
    Description: Group sessions teaching time management, relaxation, and resilience.
    Purpose: Equips patients to handle emotional ups and downs of chronic disease.
    Mechanism: Lowered stress correlates with fewer inflammatory flares KargerAAO.

20. Caregiver Training
    Description: Instructional sessions for family on disease basics and assistance techniques.
    Purpose: Ensures supportive home environment and proper eye-drop administration.
    Mechanism: Educated caregivers help maintain adherence and spot early warning signs Uveitis.org | OIUFPatient.

Key Pharmacological Treatments

Below are ten cornerstone medications. For each, dosage, drug class, administration schedule, and common side effects are detailed.

1. Prednisone (Oral Corticosteroid)

   • Dosage: Start at 1 mg/kg/day (max 60 mg) for acute flares, taper by 5 mg/week.

   • Class: Systemic corticosteroid.

   • Timing: Single morning dose to mimic circadian cortisol.

   • Side Effects: Weight gain, hypertension, hyperglycemia, osteoporosis, mood swings.

2. Prednisolone Acetate 1% (Topical Steroid)

   • Dosage: One drop every 2 hours while awake for active inflammation, then taper over 6–8 weeks.

   • Class: Topical corticosteroid.

   • Timing: Throughout waking hours, spacing doses evenly.

   • Side Effects: Elevated intraocular pressure, cataract formation, delayed wound healing.

3. Triamcinolone Acetonide (Periocular Injection)

   • Dosage: 20–40 mg sub-Tenon’s injection every 3–4 months as needed.

   • Class: Local corticosteroid injection.

   • Timing: Single injection per treatment cycle.

   • Side Effects: Localized ocular hypertension, orbital fat atrophy, ptosis.

4. Fluocinolone Acetonide Intravitreal Implant (Iluvien)

   • Dosage: 0.18 mg implant placed via pars plana, lasting up to 36 months.

   • Class: Long-acting intravitreal corticosteroid.

   • Timing: Single implantation per eye.

   • Side Effects: High risk of steroid-response glaucoma, cataract progression EyeWiki.

5. Bevacizumab (Avastin)

   • Dosage: 1.25 mg intravitreal injection every 4–6 weeks for neovascular suppression.

   • Class: Anti-VEGF monoclonal antibody.

   • Timing: Monthly injections initially, then PRN based on OCT.

   • Side Effects: Endophthalmitis risk, transient intraocular inflammation.

6. Ranibizumab (Lucentis)

   • Dosage: 0.5 mg intravitreal injection monthly for 3 months, then PRN.

   • Class: Anti-VEGF Fab fragment.

   • Timing: Monthly loading doses, then as needed.

   • Side Effects: Rare systemic thromboembolic events, eye pain.

7. Aflibercept (Eylea)

   • Dosage: 2 mg intravitreal injection every 8 weeks after 3 initial monthly doses.

   • Class: VEGF-trap fusion protein.

   • Timing: 3 monthly loading, then bi-monthly maintenance.

   • Side Effects: Elevated intraocular pressure, conjunctival hemorrhage.

8. Methotrexate (Systemic Immunosuppressant)

   • Dosage: 15–25 mg subcutaneous weekly, with folinic acid rescue.

   • Class: Antimetabolite immunosuppressant.

   • Timing: Once weekly.

   • Side Effects: Hepatotoxicity, bone marrow suppression, mucositis.

9. Azathioprine

   • Dosage: 1–2 mg/kg/day orally.

   • Class: Purine analog immunosuppressant.

   • Timing: Daily.

   • Side Effects: Leukopenia, hepatotoxicity, increased infection risk.

10. Infliximab (Remicade)

• Dosage: 5 mg/kg intravenous infusion at weeks 0, 2, 6, then every 8 weeks.

• Class: Anti-TNF-α monoclonal antibody.

• Timing: Loading then maintenance infusions.

• Side Effects: Infusion reactions, latent tuberculosis reactivation.

---

Dietary Molecular Supplements

These supplements may support retinal health by reducing oxidative stress and modulating inflammation.

1. Vitamin A (Retinol)

   • Dosage: 3,000 IU/day.

   • Function: Essential for photoreceptor function.

   • Mechanism: Maintains rod and cone pigment regeneration.

2. Vitamin C (Ascorbic Acid)

   • Dosage: 500 mg twice daily.

   • Function: Water-soluble antioxidant.

   • Mechanism: Scavenges free radicals in ocular tissues.

3. Vitamin E (α-Tocopherol)

   • Dosage: 400 IU/day.

   • Function: Lipid-soluble antioxidant.

   • Mechanism: Protects photoreceptor membranes from peroxidation.

4. Zinc

   • Dosage: 40 mg elemental zinc/day.

   • Function: Cofactor for antioxidant enzymes.

   • Mechanism: Stabilizes cell membranes and supports superoxide dismutase.

5. Omega-3 Fatty Acids (DHA/EPA)

   • Dosage: 1,000 mg DHA + 500 mg EPA daily.

   • Function: Anti-inflammatory lipid mediators.

   • Mechanism: Reduces cytokine production and vascular permeability.

6. Lutein

   • Dosage: 10 mg/day.

   • Function: Macular pigment enhancement.

   • Mechanism: Filters blue light and neutralizes reactive oxygen species.

7. Zeaxanthin

   • Dosage: 2 mg/day.

   • Function: Supports central retinal health.

   • Mechanism: Synergizes with lutein for macular protection.

8. Curcumin

   • Dosage: 500 mg twice daily.

   • Function: Natural anti-inflammatory.

   • Mechanism: Inhibits NF-κB and downregulates TNF-α production.

9. Resveratrol

   • Dosage: 150 mg/day.

   • Function: Polyphenolic antioxidant.

   • Mechanism: Activates SIRT1, promoting cell survival pathways.

10. Quercetin

• Dosage: 500 mg twice daily.

• Function: Bioflavonoid with anti-angiogenic effects.

• Mechanism: Inhibits VEGF signaling and vascular permeability.

---

Emerging Pharmacological Approaches

These therapies are investigational or off-label, focusing on novel mechanisms.

1. Alendronate (Bisphosphonate)

   • Dosage: 70 mg orally weekly.

   • Function: Anti-angiogenic potential.

   • Mechanism: Inhibits farnesyl pyrophosphate synthase, reducing endothelial proliferation.

2. Risedronate (Bisphosphonate)

   • Dosage: 35 mg orally weekly.

   • Function: Modulates inflammatory cell activity.

   • Mechanism: Reduces macrophage-mediated cytokine release.

3. Recombinant Human FGF2 (Regenerative)

   • Dosage: Intravitreal 50 µg monthly (investigational).

   • Function: Stimulates neuronal and vascular repair.

   • Mechanism: Binds FGFR, promoting Müller cell survival and angiostatic balance.

4. PEDF-Derived Peptides (Regenerative)

   • Dosage: Intravitreal injections every 8 weeks (trial doses).

   • Function: Neuroprotective and anti-angiogenic.

   • Mechanism: Inhibits VEGF and supports photoreceptor integrity.

5. Hyaluronic Acid Vitreous Substitute (Viscosupplementation)

   • Dosage: Single pars plana injection at vitrectomy (exact dose varies).

   • Function: Restores vitreous volume and damping.

   • Mechanism: Provides scaffold for controlled drug release and mechanical support.

6. Mesenchymal Stem Cell Injection (Stem Cell Therapy)

   • Dosage: Sub-Tenon’s or intravitreal 1×10⁶ cells (ongoing trials).

   • Function: Anti-inflammatory and regenerative.

   • Mechanism: Secretes trophic factors (e.g., HGF, TSG-6) that modulate immune response and promote retinal repair.

---

Surgical Interventions

When medical therapy is insufficient, surgical procedures can restore anatomy and control complications.

1. Pars Plana Vitrectomy (PPV)

   • Procedure: Removal of vitreous gel via three-port entry, clearing inflammatory debris and membranes.

   • Benefits: Reduces cytokine load, allows direct membrane peeling, and facilitates drug delivery EyeWiki.

2. Epiretinal Membrane Peeling

   • Procedure: Carefully lifting fibrocellular membranes from the retinal surface under visualization.

   • Benefits: Relieves retinal traction, improves macular contour, and may enhance visual acuity.

3. Panretinal Photocoagulation (PRP)

   • Procedure: Laser burns applied across peripheral retina to regress neovascularization.

   • Benefits: Reduces VEGF drive, prevents vitreous hemorrhage, and lowers risk of neovascular glaucoma.

4. Cataract Extraction with Intraocular Lens Implantation

   • Procedure: Phacoemulsification of the crystalline lens and placement of a foldable intraocular lens.

   • Benefits: Addresses steroid-induced or disease-related cataracts, improving rehabilitation of vision.

5. Glaucoma Drainage Device Placement

   • Procedure: Implantation of Ahmed or Baerveldt valve to shunt aqueous humor.

   • Benefits: Controls steroid-response or neovascular glaucoma pressure spikes that are refractory to medications.

---

Preventive Measures

Preventing exacerbations and preserving remaining vision involves lifestyle and environmental modifications:

1. Genetic counseling for at-risk family members

2. Avoiding tobacco smoke and second-hand exposure

3. Wearing UV-blocking sunglasses outdoors

4. Maintaining tight control of systemic comorbidities (e.g., diabetes, hypertension)

5. Adhering to a Mediterranean-style, antioxidant-rich diet

6. Regular moderate exercise (≥150 minutes/week)

7. Moderating alcohol intake (<1 drink/day for women, <2 for men)

8. Ensuring adequate sleep hygiene (7–8 hours/night)

9. Keeping indoor air quality high (humidifiers/HEPA filters to reduce irritants)

10. Scheduling routine comprehensive eye exams at least twice yearly

---

When to See Your Doctor

Seek prompt medical attention if you experience:

• Sudden decrease in vision or new blind spots

• Intense eye pain or headache with redness

• New floaters, flashes of light, or curtain-like vision loss

• Severe sensitivity to light (photophobia)

• Uncontrolled eye pressure symptoms (halos around lights)

---

“Do’s” and “Don’ts”

Do:

1. Follow your medication schedule exactly as prescribed

2. Use prescribed eye drops at recommended intervals

3. Keep a symptom diary and share it at visits

4. Apply cold compresses for mild eye discomfort

5. Wear protective eyewear during sports or chores

Avoid:
6. Rubbing or pressing on inflamed eyes
7. Missing outpatient follow-up or lab testing appointments
8. Self-medicating with over-the-counter NSAID drops without approval
9. Exposure to smoky or dusty environments
10. Skipping vaccinations (e.g., influenza) that can trigger systemic inflammation

---

Frequently Asked Questions (FAQs)

1. What is the cause of ADNIV?
   ADNIV is caused by dominant missense mutations in the CAPN5 gene, leading to toxic hyperactivity of the calpain-5 enzyme in retinal cells Via Medica Journals.

2. How is ADNIV inherited?
   It follows an autosomal dominant pattern: each child of an affected parent has a 50% chance of inheriting the mutation.

3. At what age do symptoms begin?
   Onset typically occurs between the second and fourth decades of life, but initial signs may be subtle and underdiagnosed.

4. Can ADNIV be cured?
   There is currently no cure. Management focuses on controlling inflammation, preventing complications, and preserving vision.

5. Is genetic testing available?
   Yes. Clinical genetic laboratories offer CAPN5 mutation analysis for definitive diagnosis and family counseling.

6. What are the main treatments?
   Long-term corticosteroids (topical, systemic, or implant), anti-VEGF agents, immunosuppressants, and timely vitrectomy or laser procedures form the treatment backbone EyeWiki.

7. How often should I have follow-up exams?
   Typically every 1–3 months or more frequently during active inflammation or after surgical interventions.

8. Can lifestyle changes slow disease progression?
   Yes. Regular exercise, healthy diet, UV protection, and stress management can help modulate systemic inflammation.

9. Are there risks with long-term steroid use?
   Chronic steroids can cause cataracts, glaucoma, hypertension, and osteoporosis; careful monitoring is essential.

10. What surgical risks exist?
    Vitrectomy and implants carry risks of infection, bleeding, and increased intraocular pressure but can be vision-saving.

11. Is low-vision rehabilitation helpful?
    Absolutely. Occupational therapy, Magnifier use, and adaptive technologies enhance daily function as vision declines.

12. Do children require different management?
    Pediatric cases often present later symptomatically; genetic confirmation is vital, and dosing adjustments are needed for weight and growth.

13. Are clinical trials available?
    Emerging RNA-interference therapies and novel anti-calpain agents are under investigation; referral to specialized centers is recommended.

14. Can pregnancy affect ADNIV?
    Hormonal changes may modulate immune activity; close obstetric-ophthalmic collaboration is advised.

15. What is the long-term outlook?
    Without aggressive, sustained therapy, most patients progress to severe vision loss by their sixth decade; proactive management can delay this trajectory.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 14, 2025.